je.st
news
ECC - More Setback Leave PI3Ks In Immuno-Oncology's Shadow
2015-09-27 17:27:14| Biotech - Topix.net
Roche must be wondering how its cross-town rival Novartis has managed to show so much progress in the otherwise disappointing PI3K inhibitor class of cancer projects. Its earliest candidate in this class, pictilisib, has stumbled badly in a breast cancer trial at a time when Novartis is preparing to file buparlisib in the same disease.
Tags: leave
shadow
ecc
setback
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||